N ormal hemostasis is maintained through a series of complex interactions between the blood coagulation proteins and the vascular endothelium. Exposure of circulating blood to subendothelial structures or artificial surfaces can initiate activation of platelets and the coagulation system, ultimately resulting in thrombus formation. 13 The relative contributions of the individual components in this process remain unclear; however, the recent identification and characterization of potent and specific inhibitors of coagulation proteins and platelet activation have advanced knowledge in this area. For example, the pivotal role of the platelet fibrinogen receptor glycoprotein (GP) Ilb/IIIa (GPIIb/IIIa) in arterial thrombosis has been well established in canine 4 - 6 and nonhuman primate 7 ' 8 models of thrombosis using selective antagonists of this receptor. Using the direct thrombin inhibitor recombinant hirudin 9 -12 and agents that limit thrombin generation, such as activated protein C, 13 factor Xa inhibitors, 14 -' 6 and tissue factor pathway inhibitor, 17 thrombin has been identified as a key clotting factor involved in the promotion of arterial thrombogenesis.
The interaction between blood platelets and collagen is of primary importance in the pathogenesis of thrombosis and atherosclerosis and in the maintenance of normal hemostasis. 18 The role of collagen in normal hemostasis is supported by studies demonstrating that patients whose platelets show a lack of responsiveness to collagen have mild bleeding problems. 1924 Although platelet adhesion, spreading, and aggregation in response to collagen in these patients were compromised, the platelets responded normally to other agonists. It was determined that either these patients had antibodies against platelet GPIalla, 21 GPVI, 22 or an unidentified platelet protein of molecular weight 85 kD 23 or that their platelets lacked normal GPIalla.
1920 - 24 Several natural inhibitors of collagen-induced aggregation and platelet adhesion to collagen, including a 50-kD protein from Bothrops atrox snake venom 25 and a 65-kD protein from Hirudo medicinalis leech saliva, 26 as well as monoclonal antibodies against the a2/3rintegrin or platelet GPIalla, 27 29 have been described. However, the lack of activity in plasma or limited availability has not allowed for their use in in vivo studies. We recently identified and isolated from salivary gland extracts of the leech Haementeria officinalis a selective inhibitor of collagen-mediated platelet aggregation in plasma and the adhesion of platelets to collagen under static conditions. 3032 This inhibitor, named leech antiplatelet protein (LAPP), has no effect on platelet aggregation stimulated by ADP, thrombin, arachidonic acid, U46619, or A23187. Recombinant LAPP (rLAPP) has been cloned and expressed in Saccharomyces cerevisiae yeast. Thus, rLAPP provides a pharmacological tool appropriate for investigating the role of collagen-dependent aggregation in animal models of thrombosis.
Therefore, we evaluated the antithrombotic effects of rLAPP in a baboon model of platelet-dependent thrombosis using collagen-coated graft segments to provide the stimulus for thrombus formation. In this model, exposure of the circulating blood to the collagen graft surface elicits reproducible thrombosis that can be inhibited by a thrombin inhibitor, recombinant hirudin, 9 and by a fibrinogen receptor antagonist, Arg-Gly-AspVal (RGDV) peptide. 8 In the present study, collagen inhibition with rLAPP was compared with a GPIIb/IIIa inhibitor, L-366,763, for antithrombotic efficacy.
Methods

Drugs and Solutions
All drugs were prepared on the day of the experiment in sterile saline. rLAPP was purified to homogeneity from a culture medium of S. cerevisiae as previously described. 31 The recombinant protein was comparable to native LAPP in its electrophoretic mobility, its reactivity with anti-LAPP antisera, and its biological activity. All studies were completed with a single lot of rLAPP. The fibrinogen receptor antagonist L-366,763 (acetylatedCys-Asn-Pro-Arg-Gly-Asp-Cys-NH 2 ) was chemically synthesized at Merck Research Laboratories.
Model Preparation
For the thrombosis model, adult male baboons (Papio anubis) weighing between 11.5 and 27.2 kg were fasted overnight and sedated with ketamine (10 mg/kg IM) and acepromazine (0.1 mg/kg IM) on the morning of the study. The animals were subsequently intubated and maintained on 2% isoflurane for the duration of the study. A Silastic femoral arteriovenous (AV) shunt was aseptically positioned approximately 2 hours before study. The AV shunt system was prepared as described by Hanson et al. 33 A 10-cm section of polyacrylamidegrafted Silastic tubing coupled with rat tail type I collagen (Dr Thomas Horbett, Center for Bioengineering, University of Washington, Seattle) was inserted into the Silastic AV shunt to provide the stimulus for thrombus formation. The method for preparation of the collagen-coated Silastic tubing has been described. 34 The type of collagen coated to the Silastic surface in the present study, rat tail type I collagen, consists of monomeric as well as cross-linked collagen.
Autologous platelets were labeled with m In-oxine (Amersham) as previously described.
14 Briefly, the platelets were isolated from whole blood by differential centrifugation. The platelet-poor plasma was decanted, and the platelet pellet was resuspended in sterile saline. '"In-oxine was added to the platelet suspension and incubated for 5 minutes at 37°C. Free ln In was removed by gentle washing with saline. The labeled platelets were then resuspended in autologous plasma and injected intravenously 1 hour before insertion of the first collagen-coated graft segment. Labeling efficiency was >90% in all studies. Deposition of '"In-labeled platelets onto the thrombogenic surface was monitored with a sodium iodide probe (Bicron, Meriden, Conn) and a multichannel analyzer (Tracor, Chicago, 111) by obtaining 1-minute acquisitions of the 173-keV peak at 5-minute intervals. The accumulation of platelets onto the graft segment was reported as the fold increase in '"In activity over baseline. Baseline values were determined by use of a 1-minute acquisition of '"In activity in a blood volume-matched segment of the Silastic AV shunt before insertion of the collagen graft. The fold increase in '"In activity over baseline was calculated by dividing the subsequent "'In activity by the baseline '"In activity at each time point, thereby adjusting for variability between animal size and amount of isotope injected.
Blood flow through the AV shunt was monitored continuously during each experiment with a Doppler ultrasonic flow meter (Baylor College of Medicine, Houston, Tex) and a transducer probe positioned on the Silastic tubing of the shunt. Flow was displayed on a Hewlett-Packard recorder (Chelmsford, Mass) and reported as the percentage of baseline flow.
Laboratory Studies
Whole blood (EDTA-anticoagulant) cell counts of platelets, erythrocytes, and white cells were determined with a Baker system 9000 counter (Baker, Allentown, Pa). Ex vivo aggregation in response to ADP (20 /xmol/L), collagen (10 Atg/mL; equine tendon collagen type I), and arachidonic acid (500 /xmol/L) was studied by evaluating light transmission through a stirred suspension of platelet-rich plasma adjusted to 2.5 xlO 8 platelets/mL with time-matched platelet-poor plasma (Chrono-Log Corp, Havertown, Pa). The adhesion of platelets to a collagen surface was carried out as previously described. 32 Fibrinogen concentration and activated partial thromboplastin times (aPTT) were determined with a Coag-A-Mate XC and standard reagents (General Diagnostics, Durham, NC). Fibrinopeptide A (FPA) values were determined by radioimmunoassay (ByK-Sangtec Diagnostica, Dietzenbach, Germany). The cross-reactivity and sensitivity of the FPA radioimmunoassay between human and baboon samples have been validated. 14 Template bleeding times were performed by use of a Simplate device (Organon Teknika, Durham, NC) on the shaved volar surface of the forearm. Briefly, the shaved medial aspect of the forearm distal to the antecubital fossa was cleansed with alcohol and permitted to air-dry for 30 seconds. A sphygmomanometer was positioned above the antecubital fossa, and the cuff was inflated to 40 mm Hg. After 30 seconds, the Simplate device was placed on the forearm about 5 to 10 cm distal to the antecubital fossa with the blade parallel to the antecubital crease. An incision was made by depressing the trigger, and the timer was simultaneously started. The flow of blood was carefully blotted at 30-second intervals until blood no longer stained the paper. Bleeding time was reported to the nearest 30 seconds.
Experimental Protocol
In preliminary (10 /ig/mL), and arachidonic acid (500 /tmol/L) and to identify a dose of rLAPP that would completely inhibit ex vivo aggregation only in response to collagen (10 /ig/mL).
According to the results of the dose-ranging studies, baboons were randomized to the following treatment groups: saline control (n=4), rLAPP (100 fig • kg" 1 • min"' IV for 120 minutes; n=5), or L-366,763 (8.5 /ig-kg"'-min~' IV for 120 minutes; n=3). The test compounds were administered via a cephalic vein catheter. The experimental protocol is represented in Fig 1. In each study, two collagen grafts were sequentially inserted into the AV shunt of each baboon. In all experiments, saline was infused during exposure to the first graft; thus, the thrombotic response to the first graft segment served as the internal control response for each baboon. After 60 minutes of exposure or immediately after occlusion of the initial collagen graft, the segment was removed and the AV shunt was reestablished. Infusion of rLAPP, L-366,763, or saline was initiated 1 hour before and maintained during exposure to the second graft. Sixty minutes after insertion of the second graft or immediately after occlusion, the Silastic shunt was removed and the baboon was allowed to recover. Each baboon received only one treatment. All procedures were reviewed and approved by the Institutional Committee for the Care and Use of Laboratory Animals and complied with federal regulations.
Statistical Analysis
Data shown represent mean±SEM. The effect of rLAPP, L-366,763, or saline on '"In-labeled platelet deposition was expressed as the fold increase from baseline. The fold increase of '"In activity was calculated by dividing subsequent '"In activity by the baseline "'In for each time point. The statistical analyses were performed on responses during the treatment graft (graft 2) and the control graft (graft 1). Repeatedmeasures ANOVA was used to compare the extent and rate of platelet deposition during the first 30 minutes of exposure to the graft in response to rLAPP, L-366,763, or saline in each animal. The significance of difference from the saline response was determined by Dunnett's test (one-sided, P<.05). A two-sided paired Student's / test was used to study differences at 30 minutes between graft 1 and graft 2 on the following parameters: aPTT, template bleeding time, thrombus weight, and FPA values.
Results
Dose-Ranging Infusion Studies
In a dose-ranging study, nine baboons were randomized to receive 60-minute graded intravenous doses of rLAPP (10, 30 , and 100 /tg • kg"' • min"'; n = 3), L-366,763 (0.85, 2.55, and 8.50 fig • kg"' • min"'; n=3), or saline (n=3). The effects of these test compounds on platelet count, template bleeding time, and inhibition of ex vivo platelet aggregation in response to ADP, collagen, and arachidonic acid are summarized in Table 1 . None of the treatments affected circulating platelet count. Template bleeding times were not increased during saline or rLAPP infusion but were dose-dependently increased (f<.05) during infusion of L-366,763. Administration of rLAPP had no effect on ex vivo aggregation of baboon platelets in response to ADP or arachidonic acid 
Thrombosis Model
For each animal, two collagen-coated graft segments were sequentially placed into the AV shunt. Saline was infused during exposure to the first graft segment in each animal to establish the thrombotic response to the collagen surface of each baboon. After 60 minutes of exposure to the first graft segment or immediately after occlusion, the initial collagen segment was removed and the AV shunt was reestablished. Therapy (saline, rLAPP, or L-366,763) was initiated 60 minutes before insertion of the second collagen graft and continued for the 60 minutes of exposure to this collagen-coated segment. The response to the second graft segment was compared with the responses to the initial, salinecontrol graft of each baboon.
Control. In the control treatment group, saline was infused during exposure to both sequentially placed collagen graft segments. As shown in Fig 2A, ' "Inlabeled platelet deposition increased maximally by 19.4±0.4-fold over the basal value after 60 minutes of exposure to the first collagen graft segment (n=3). Similarly, platelet deposition increased to 14.0±2.3-fold after 60 minutes of exposure to the second collagen graft segment. In all control studies, the rate of platelet deposition and blood flow reduction were greatest during the initial 30 minutes of exposure. Because platelet deposition was near maximum at 30 minutes and some animals occluded before the 60-minute time period, statistical comparisons of rate differences and hemostatic parameters were evaluated at 30 minutes. A comparison between the first and the second collagen grafts of the saline control animals revealed that the rate of platelet deposition during the initial 30 minutes of exposure was not different and that the rate and extent of blood flow reduction were also not different (Fig 2B) . Collagen inhibitor. In this treatment group, saline was infused during exposure to the initial graft segment, and rLAPP was infused for 60 minutes before and continued during exposure to the second graft.
ul In-labeled platelet deposition increased maximally by 14.9±1.4-fold over basal value after 60 minutes of exposure to the first (control) graft. As shown in Fig 3A, platelet deposition onto the second collagen graft segment during rLAPP infusion (100 n% • kg" 1 • min" 1 IV) increased maximally by 16.9±2.0-fold over basal value during exposure to the second graft segment. A slight but nonsignificant (P>.05) reduction in the rate of m In-labeled platelet deposition over the initial 30 minutes of exposure to the graft segment was observed during infusion of rLAPP compared with saline infusion. After 30 minutes of exposure to the initial, saline-control graft, blood flow through the AV shunt was decreased to 28 ±12% of basal flow. During rLAPP infusion, blood flow was decreased to 37 ±6% of basal flow after 30 minutes ( Fig  3B) . Although statistically insignificant, the decreased rate of blood flow diminution in the second, rLAPP segments compared with the control segments is consistent with the reduced rate of lu In-labeled platelet deposition during the initial 30 minutes of exposure to the collagen graft.
GPIIb/IIIa inhibition. In this treatment group, saline was again infused during exposure to the initial graft, and L-366,763 was infused for 60 minutes before and during exposure to the second graft.
ul In-labeled platelet deposition increased maximally by 17.8±4.9-fold over basal deposition after 60 minutes of exposure to 
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Graphs showing effect of recombinant leech antiplatelet peptide (100 kg~' • mir r1 ) on "' I n-labeled platelet deposition (A) and blood flow (B).
• and a represent data from graft 1 and graft 2 studies, respectively. In each experiment, saline was infused during exposure to graft 1 and recombinant leech antiplatelet peptide during exposure to graft 2. All values represent mean±SEM (n=5).
the initial collagen-coated graft segment. In contrast, infusion of L-366,763 during exposure to the second collagen graft resulted in a maximal increase of platelet deposition of only 2.4± 1.4-fold basal platelet deposition after 60 minutes (Fig 4A) . The rate of platelet deposition onto the collagen-coated segment was significantly (P=.O3) reduced during infusion of L-366,763 compared with saline. There was little decrease in blood flow during the initial 30-minute period during L-366,763 infusion compared with the decrease in blood flow during exposure to the initial, saline-control segment (Fig 4B) . After 60 minutes of exposure to the collagen graft segment, blood flow through the AV shunt was decreased to 18±11% of basal flow in control studies and remained within 92±6% of basal flow in animals receiving L-366,763 (Fig 4B) .
Hemostatic Parameters
The effect of saline, rLAPP, and L-366,763 on bleeding time, aPTT, FPA values, and inhibition of basal ex vivo platelet aggregation responses is shown in Table 2 . 1 ' mir T1 IV) prevented aggregation of platelets in response to all agonists throughout the study.
As expected from the results of the preliminary infusion studies, template bleeding times were not increased by infusion of saline or rLAPP; however, they were increased from 2.4 ±0.2 minutes to >10 minutes with administration of L-366,763.
Discussion
The interaction of platelets with subendothelial collagen is believed to be of primary importance in the normal hemostatic response after injury to a blood vessel. Under pathological conditions, rupture of an atherosclerotic plaque also exposes platelets to a variety of thrombogenic stimuli, including collagen. In both these cases, platelet adherence, spreading, and aggregation induced by collagen are believed to be early stimuli for thrombus formation. Direct evaluation of the role of the collagen/platelet interaction in vivo has not been possible because of a lack of a suitable inhibitor of this process. Several naturally occurring inhibitors of platelet activation by collagen, such as a 65 -kD protein from the leech H medicinalis 26 and a 50-kD protein from B atrox snake venom, 25 have been described. The potential utility of these inhibitors remains unrealized. Other inhibitors of collagen stimulation of platelets, including several monoclonal antibodies 2729 and antibodies isolated from patients whose platelets do not respond to collagen, 21 - 23 have been useful tools to study this process. However, the polyclonal antibodies are limited in availability, and the monoclonal antibodies are not effective inhibitors of collagen-stimulated aggregation 2728 or of adhesion of platelets to collagen in the presence of physiological cations. Although antibody 6F, is an inhibitor of adhesion and aggregation, it loses its potency in the presence of plasma proteins. 29 We recently reported on a naturally occurring protein, LAPP, a 16-kD protein isolated from the leech H officinalis, that blocks both platelet adhesion to collagen and collagen-induced aggregation. 3031 The successful expression of rLAPP in yeast 32 has allowed the production of sufficient quantity of LAPP to permit evaluation of a specific inhibitor of platelet activation by collagen in vivo in an animal model of thrombosis.
In the dose-ranging study, we demonstrated that rLAPP dose-dependently inhibits collagen-induced ex vivo aggregation of platelets in anesthetized baboons without affecting platelet count or platelet aggregation in response to ADP or arachidonic acid. Our results are consistent with the specificity of LAPP described in an in vitro assay using human platelets in which LAPP prevented aggregation in response to collagen but not to ADP, U46619, A23187, thrombin, or arachidonic acid. 30 In the baboon model of collagen graft thrombosis, a platelet-dependent thrombus forms after insertion of a collagen-coated graft segment of a femoral AV shunt in anesthetized baboons. The resulting thrombus in this experimental setting is resistant to heparin and aspirin but can be prevented by infusion of the thrombin inhibitor hirudin 9 or RGDV-based peptides. 8 The Silastic tubing coated with rat tail type I collagen to render a thrombogenic surface provides a unique opportunity to investigate the effect of the specific inhibitors under the controlled conditions of this model. Since rLAPP blocks the initial platelet/collagen interaction, it would be expected to act at a stage of platelet deposition proximal to that at which either a thrombin inhibitor or a fibrinogen receptor antagonist, which inhibits platelet/ platelet interaction, is effective.
Inhibition of thrombus formation during infusion of L-366,763 was expected from previous studies of monoclonal antibodies to the human fibrinogen receptor GPIIb/IIIa and of nonpeptide mimetics and synthetic peptides comprising short amino acid sequences that compete with fibrinogen for binding sites on the GPIIb/ Ilia complex. 48 The marked antithrombotic effect of L-366,763 supports a pivotal role of platelets in a setting of high-flow thrombosis and confirms that fibrinogen binding to the platelet integrin GPIIb/IIIa is essential for platelet aggregation and platelet deposition on the thrombogenic surface of the present model, regardless of the agonist or pathway responsible for platelet activation. Alteration of hemostatic function, as evidenced by increased bleeding times, was coincident with antithrombotic efficacy. This result is consistent with others using a monoclonal antibody to GPIIb/IIIa, 35 in which bleeding time elevation correlated with the extent of inhibition of platelet aggregation.
In this study, a dose of the specific collagen inhibitor rLAPP that completely inhibited collagen-induced platelet aggregation did not inhibit the rate or extent of platelet deposition or the diminution of blood flow. The lack of antithrombotic efficacy of rLAPP in this model was unexpected, since a collagen-coated surface was used as the stimulus for platelet deposition. Earlier in vitro studies demonstrating that rLAPP inhibits collagen-induced platelet activation and the static adhesion of human platelets 32 were repeated using baboon platelets. Baboon platelet adhesion to the collagen graft was also inhibited by rLAPP (data not shown). Thus, the lack of an effect of rLAPP to inhibit platelet deposition in this model is not due to a difference in rLAPP interaction with platelets from a different species. Additionally, rLAPP effectively inhibits in vitro platelet aggregation elicited by multiple sources of collagen, including the collagen used to coat the Silastic tubing in this study, rat tail type I, and equine tendon type I used in the present ex vivo studies (data not shown). The dosage of rLAPP used was adequate to completely inhibit collagen-induced aggregation, but we cannot rule out the possibility that a higher concentration of rLAPP is required to inhibit platelet deposition on the grafts than to fully inhibit collagen-stimulated aggregation. This seems unlikely because, as described above, a thrombin inhibitor, 9 an RGDV peptide, 8 and L-366,763 in the current study are effective inhibitors of platelet deposition on the collagen-coated graft surface at concentrations that fully inhibited platelet aggregation.
There are several possible explanations for the absence of an antithrombotic benefit of rLAPP in this study. Although rLAPP has been shown to inhibit platelet adhesion to collagen and collagen-stimulated dense-granule release in static models, 31 - 32 it is possible that collagen-mediated platelet adhesion under the flow conditions of this model is not affected by rLAPP. In vitro, rLAPP inhibits human platelet adhesion to spraycoated collagen types I, HI, and IV under high-shear conditions (approximately 1600 second" 1 ); however, at least 10-fold more rLAPP was required to observe inhibition of platelet adhesion at lower shear forces (approximately 300 second" 1 ). In the present model, shear force is approximately 500 second" 1 . 36 Second, other platelet/collagen interactions not affected by rLAPP may occur. Finally, previous studies demonstrate that collagen-independent mechanisms mediate the thrombotic response in this model. The effectiveness of fibrinogen receptor antagonists 78 and a thrombin inhibitor 9 demonstrates that the thrombotic event is dependent on both platelet activation and thrombin generation.
Although a collagen-coated segment was used as the thrombotic stimulus, it is possible that this surface elicited responses characteristic of exposure to an artificial surface. For instance, after exposure of an artificial surface to blood in an ex vivo flow chamber, there is a lag period of approximately 1 minute before platelet adherence is evident. 37 During this period, plasma proteins, predominantly fibrinogen, are adsorbed to the surface. McManama and colleagues 38 conducted experiments in which soluble polymers composed of crosslinked fibrinogen molecules were found to activate platelets and to lead to their aggregation and secretion. Thus, surface-adsorbed fibrinogen may alter the biological reactivity of the surface and promote thrombus formation via GPIIb/IIIa. The interaction of platelets with this surface would not be expected to be inhibited by rLAPP. Furthermore, artificial materials have been shown to activate coagulation factor XII, with subsequent involvement of the intrinsic coagulation system, ultimately leading to the formation of thrombin. 39 Demonstration of elevated FPA levels arising from the action of thrombin during exposure to the collagencoated graft segment supports the contention that the coagulation system is activated in this model. Neither rLAPP nor L-366,763 attenuated the increase in thrombin-mediated cleavage of fibrinogen to fibrin, as evidenced by increased FPA levels during infusion of both inhibitors. The sharply contrasting effects of the collagen-specific inhibitor rLAPP and the fibrinogen receptor antagonist L-366,763 could therefore not be attributed to differences in the generation of thrombin. It is interesting that despite the absence of significant platelet accumulation on the graft, prothrombinase complexes are still formed and thrombin is generated.
The lack of effect of rLAPP on template bleeding times at doses that fully inhibit platelet aggregation in response to collagen was unexpected. In patients with a deficiency of or a neutralizing antibody to GPIa/IIa, 1921 GPVI, 22 or the 85-to 90-kD platelet protein, 23 template bleeding times are typically prolonged and clinical bleeding disorders ranging from mild to severe result. However, abnormal hemostatic function is not characteristic of all patients with deficiencies of GPIV. 40 In these subjects, platelet aggregation is inhibited only to collagen type V. 4142 Thus, elucidation of the molecular mechanism of action of rLAPP-mediated inhibition of collagen-stimulated platelet aggregation is required to understand the apparent contribution of collagen to template bleeding time in anesthetized baboons in which inhibition of collagen-stimulated platelet aggregation does not affect bleeding time or platelet deposition on the collagen-coated surface.
In conclusion, we have shown that systemic infusion of the leech-derived peptide rLAPP can selectively and completely inhibit ex vivo aggregation of platelets in response to collagen in anesthetized baboons; however, this effect does not confer an antithrombotic benefit on exposure to a collagen-coated graft segment. The superior antithrombotic efficacy of the fibrinogen receptor antagonist L-366,763 indicates that mechanisms of platelet activation other than the initial collagen/platelet interaction are crucial for the development of platelet-dependent thrombosis in this baboon model.
